Fuse Medical, Inc. (FZMD) intrinsic value & 10-year financials
Fuse Medical, Inc. (FZMD) has a Graham intrinsic value of $0.26 per share. At $0.03 on Oct 17, 2026, the stock trades 88% below that value. Over the last 10 fiscal years revenue grew 37.5% a year to $18.6M, with an average return on invested capital of -613.8%.
- Graham intrinsic value
- $0.26
- Share price (Oct 17, 2026)
- $0.03
- Price vs Graham value
- 88% below
- Market cap
- $2.3M
- Revenue (FY2022)
- $18.6M
- Revenue growth (10-yr CAGR)
- 37.5%
- ROIC (10-yr avg)
- -613.8%
- Free cash flow (FY2022)
- —
FZMD 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2022 | $18.6M | $3.1M | $0.04 | — | -4.4% | 43.2% |
| FY2021 | $20.4M | -$1.6M | -$0.02 | — | -10.8% | 79.2% |
| FY2020 | $21.4M | -$1.4M | -$0.02 | $215.9K | -4.8% | 61.6% |
| FY2019 | $22.9M | -$3.3M | -$0.05 | -$20.1K | -19.0% | -3557.5% |
| FY2018 | $26.3M | $4.0M | $0.06 | $2.4M | -7.4% | 60.1% |
| FY2017 | $26.4M | $699.7K | $0.04 | $1.6M | 3.1% | -20.5% |
| FY2016 | $25.7M | -$585.9K | $0.33 | — | -1.9% | -508.3% |
| FY2015 | $1.7M | -$801.5K | — | -$383.4K | -47.2% | -818.2% |
| FY2014 | $941.1K | -$1.4M | — | -$1.2M | -141.8% | -1760.1% |
| FY2013 | $1.1M | -$109.9K | — | -$52.6K | -10.3% | 282.8% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Fuse Medical, Inc. is a consistent compounder, expanding top-line revenue at 37.5% annually over the past decade.
Fuse Medical, Inc. has earned high returns on invested capital, averaging 16.0% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.
Fuse Medical, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Fuse Medical, Inc. is modeled at -0.5% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $0.26 per share.